Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Payables (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Payables for 16 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • Quarterly Payables rose 12.9% to $2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, up 12.9% year-over-year, with the annual reading at $2.5 million for FY2025, 12.9% up from the prior year.
  • Payables hit $2.5 million in Q4 2025 for Guided Therapeutics, down from $2.8 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $2.8 million in Q3 2025 to a low of $51770.0 in Q1 2023.
  • Historically, Payables has averaged $2.0 million across 5 years, with a median of $2.2 million in 2022.
  • Biggest five-year swings in Payables: plummeted 97.92% in 2023 and later skyrocketed 3662.8% in 2024.
  • Year by year, Payables stood at $135000.0 in 2021, then skyrocketed by 1561.16% to $2.2 million in 2022, then dropped by 8.59% to $2.0 million in 2023, then grew by 8.93% to $2.2 million in 2024, then grew by 12.9% to $2.5 million in 2025.
  • Business Quant data shows Payables for GTHP at $2.5 million in Q4 2025, $2.8 million in Q3 2025, and $2.7 million in Q2 2025.